The chief executive of AAH Pharmaceuticals David Bound, has decided to step down and will leave the organisation at the end of this year, Pharmacy Business can exclusively reveal.
Bound took over as CEO of the drug wholesaler in 2022, having previously held various positions within the company for over a decade.
He has extensive experience in the healthcare industry, as well as in supply chain management, operations, and trading.
Under his leadership, the firm last year published its Carbon Reduction Plan, committing to achieve Net Zero emissions by 2045.
He has also led the digital transformation of the business, launching a new Returns platform and AAH Connect+, their new Patient Medication Record (PMR) package, used by over 5,000 pharmacies across the UK by the end of 2024.
His tenure is also marked by a consistent and vocal commitment to championing the needs of pharmaceutical wholesalers and the wider medicines supply chain. During a visit by health and social care minister Karin Smyth to AAH facility in Bristol, he highlighted issues like the increasing cost to serve for low margin businesses, product availability and shortages, workforce churn and cost, red tape, and more.
He also raised AAH’s concerns about the fragility of community pharmacy and the urgent need for enhanced funding to support its long-term sustainability.